Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ZR-75-1 | HR+ | Luminal | IKK16 | IKK | NFKB | 66.7 | uM | 10444.093 | 0.0108 | -0.9686 | 1.0902 | |
| 184A1 | NM | Basal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00145 | uM | 5895.091 | 0.9776 | 0.9618 | 1.1729 | |
| 184A1 | NM | Basal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00723 | uM | 5895.091 | 1.1560 | 1.2631 | 1.1729 | |
| 184A1 | NM | Basal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.0362 | uM | 5895.091 | 1.0373 | 1.0635 | 1.1729 | |
| 184A1 | NM | Basal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.181 | uM | 5895.091 | 1.0596 | 1.1011 | 1.1729 | |
| 184A1 | NM | Basal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.904 | uM | 5895.091 | 1.0734 | 1.1244 | 1.1729 | |
| 184A1 | NM | Basal | Imatinib | ABL/KIT/PDGFR | nRTK | 4.52 | uM | 5895.091 | 0.9329 | 0.8850 | 1.1729 | |
| 184A1 | NM | Basal | Imatinib | ABL/KIT/PDGFR | nRTK | 22.6 | uM | 5895.091 | 0.5413 | 0.1850 | 1.1729 | |
| 184A1 | NM | Basal | Imatinib | ABL/KIT/PDGFR | nRTK | 113 | uM | 5895.091 | 0.0105 | -0.9590 | 1.1729 | |
| 184A1 | NM | Basal | Imatinib | ABL/KIT/PDGFR | nRTK | 565 | uM | 5895.091 | 0.0020 | -0.9899 | 1.1729 | |
| 184B5 | NM | Basal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00145 | uM | 5896.091 | 0.9301 | 0.9056 | 1.4988 | |
| 184B5 | NM | Basal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00723 | uM | 5896.091 | 0.9390 | 0.9178 | 1.4988 | |
| 184B5 | NM | Basal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.0362 | uM | 5896.091 | 0.9679 | 0.9570 | 1.4988 | |
| 184B5 | NM | Basal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.181 | uM | 5896.091 | 0.9829 | 0.9771 | 1.4988 | |
| 184B5 | NM | Basal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.904 | uM | 5896.091 | 0.9409 | 0.9204 | 1.4988 | |
| 184B5 | NM | Basal | Imatinib | ABL/KIT/PDGFR | nRTK | 4.52 | uM | 5896.091 | 0.9355 | 0.9130 | 1.4988 | |
| 184B5 | NM | Basal | Imatinib | ABL/KIT/PDGFR | nRTK | 22.6 | uM | 5896.091 | 0.6687 | 0.5291 | 1.4988 | |
| 184B5 | NM | Basal | Imatinib | ABL/KIT/PDGFR | nRTK | 113 | uM | 5896.091 | 0.0110 | -0.9015 | 1.4988 | |
| 184B5 | NM | Basal | Imatinib | ABL/KIT/PDGFR | nRTK | 565 | uM | 5896.091 | 0.0041 | -0.9493 | 1.4988 | |
| 184B5 | NM | Basal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00145 | uM | 5897.091 | 0.9614 | 0.9369 | 1.2296 | |
| 184B5 | NM | Basal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00723 | uM | 5897.091 | 1.0153 | 1.0248 | 1.2296 | |
| 184B5 | NM | Basal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.0362 | uM | 5897.091 | 0.9987 | 0.9980 | 1.2296 | |
| 184B5 | NM | Basal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.181 | uM | 5897.091 | 0.9884 | 0.9811 | 1.2296 | |
| 184B5 | NM | Basal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.904 | uM | 5897.091 | 0.9952 | 0.9921 | 1.2296 | |
| 184B5 | NM | Basal | Imatinib | ABL/KIT/PDGFR | nRTK | 4.52 | uM | 5897.091 | 0.9826 | 0.9716 | 1.2296 |